CSF biomarker and PIB-PET-derived beta-amyloid signature predicts metabolic, gray matter, and cognitive changes in nondemented subjects

Michael Ewers, Philip Insel, William J. Jagust, Leslie Shaw, John Q. Trojanowski J, Paul Aisen, Ronald Carl Petersen, Norbert Schuff, Michael W. Weiner

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

Beta-amyloid (Aβ) is a histopathological hallmark of Alzheimer's disease dementia, but high levels of Aβ in the brain can also be found in a substantial proportion of nondemented subjects. Here we investigated which 2-year rate of brain and cognitive changes are present in nondemented subjects with high and low Aβ levels, as assessed with cerebrospinal fluid and molecular positron emission tomography (PET)-based biomarkers of Aβ. In subjects with mild cognitive impairment, increased brain Aβ levels were associated with significantly faster cognitive decline, progression of gray matter atrophy within temporal and parietal brain regions, and a trend for a faster decline in parietal Fludeoxyglucose (FDG)-PET metabolism. Changes in gray matter and FDG-PET mediated the association between Aβ and cognitive decline. In contrast, elderly cognitively healthy controls (HC) with high Aβ levels showed only a faster medial temporal lobe and precuneus volume decline compared with HC with low Aβ. In conclusion, the current results suggest not only that both functional and volumetric brain changes are associated with high Aβ years before the onset of dementia but also that HC with substantial Aβ levels show higher Aβ pathology resistance, lack other pathologies that condition neurotoxic effects of Aβ, or accumulated Aβ for a shorter time period.

Original languageEnglish (US)
Pages (from-to)1993-2004
Number of pages12
JournalCerebral Cortex
Volume22
Issue number9
DOIs
StatePublished - Sep 2012

Fingerprint

Amyloid
Positron-Emission Tomography
Biomarkers
Brain
Parietal Lobe
Alzheimer Disease
Pathology
Temporal Lobe
Atrophy
Cerebrospinal Fluid
Dementia
Gray Matter
Cognitive Dysfunction

Keywords

  • FDG-PET
  • MCI
  • PIB-PET

ASJC Scopus subject areas

  • Cognitive Neuroscience
  • Cellular and Molecular Neuroscience

Cite this

Ewers, M., Insel, P., Jagust, W. J., Shaw, L., Trojanowski J, J. Q., Aisen, P., ... Weiner, M. W. (2012). CSF biomarker and PIB-PET-derived beta-amyloid signature predicts metabolic, gray matter, and cognitive changes in nondemented subjects. Cerebral Cortex, 22(9), 1993-2004. https://doi.org/10.1093/cercor/bhr271

CSF biomarker and PIB-PET-derived beta-amyloid signature predicts metabolic, gray matter, and cognitive changes in nondemented subjects. / Ewers, Michael; Insel, Philip; Jagust, William J.; Shaw, Leslie; Trojanowski J, John Q.; Aisen, Paul; Petersen, Ronald Carl; Schuff, Norbert; Weiner, Michael W.

In: Cerebral Cortex, Vol. 22, No. 9, 09.2012, p. 1993-2004.

Research output: Contribution to journalArticle

Ewers, M, Insel, P, Jagust, WJ, Shaw, L, Trojanowski J, JQ, Aisen, P, Petersen, RC, Schuff, N & Weiner, MW 2012, 'CSF biomarker and PIB-PET-derived beta-amyloid signature predicts metabolic, gray matter, and cognitive changes in nondemented subjects', Cerebral Cortex, vol. 22, no. 9, pp. 1993-2004. https://doi.org/10.1093/cercor/bhr271
Ewers, Michael ; Insel, Philip ; Jagust, William J. ; Shaw, Leslie ; Trojanowski J, John Q. ; Aisen, Paul ; Petersen, Ronald Carl ; Schuff, Norbert ; Weiner, Michael W. / CSF biomarker and PIB-PET-derived beta-amyloid signature predicts metabolic, gray matter, and cognitive changes in nondemented subjects. In: Cerebral Cortex. 2012 ; Vol. 22, No. 9. pp. 1993-2004.
@article{34984c9ba0664d92ba4e53b01e015b1a,
title = "CSF biomarker and PIB-PET-derived beta-amyloid signature predicts metabolic, gray matter, and cognitive changes in nondemented subjects",
abstract = "Beta-amyloid (Aβ) is a histopathological hallmark of Alzheimer's disease dementia, but high levels of Aβ in the brain can also be found in a substantial proportion of nondemented subjects. Here we investigated which 2-year rate of brain and cognitive changes are present in nondemented subjects with high and low Aβ levels, as assessed with cerebrospinal fluid and molecular positron emission tomography (PET)-based biomarkers of Aβ. In subjects with mild cognitive impairment, increased brain Aβ levels were associated with significantly faster cognitive decline, progression of gray matter atrophy within temporal and parietal brain regions, and a trend for a faster decline in parietal Fludeoxyglucose (FDG)-PET metabolism. Changes in gray matter and FDG-PET mediated the association between Aβ and cognitive decline. In contrast, elderly cognitively healthy controls (HC) with high Aβ levels showed only a faster medial temporal lobe and precuneus volume decline compared with HC with low Aβ. In conclusion, the current results suggest not only that both functional and volumetric brain changes are associated with high Aβ years before the onset of dementia but also that HC with substantial Aβ levels show higher Aβ pathology resistance, lack other pathologies that condition neurotoxic effects of Aβ, or accumulated Aβ for a shorter time period.",
keywords = "Aβ, FDG-PET, MCI, PIB-PET",
author = "Michael Ewers and Philip Insel and Jagust, {William J.} and Leslie Shaw and {Trojanowski J}, {John Q.} and Paul Aisen and Petersen, {Ronald Carl} and Norbert Schuff and Weiner, {Michael W.}",
year = "2012",
month = "9",
doi = "10.1093/cercor/bhr271",
language = "English (US)",
volume = "22",
pages = "1993--2004",
journal = "Cerebral Cortex",
issn = "1047-3211",
publisher = "Oxford University Press",
number = "9",

}

TY - JOUR

T1 - CSF biomarker and PIB-PET-derived beta-amyloid signature predicts metabolic, gray matter, and cognitive changes in nondemented subjects

AU - Ewers, Michael

AU - Insel, Philip

AU - Jagust, William J.

AU - Shaw, Leslie

AU - Trojanowski J, John Q.

AU - Aisen, Paul

AU - Petersen, Ronald Carl

AU - Schuff, Norbert

AU - Weiner, Michael W.

PY - 2012/9

Y1 - 2012/9

N2 - Beta-amyloid (Aβ) is a histopathological hallmark of Alzheimer's disease dementia, but high levels of Aβ in the brain can also be found in a substantial proportion of nondemented subjects. Here we investigated which 2-year rate of brain and cognitive changes are present in nondemented subjects with high and low Aβ levels, as assessed with cerebrospinal fluid and molecular positron emission tomography (PET)-based biomarkers of Aβ. In subjects with mild cognitive impairment, increased brain Aβ levels were associated with significantly faster cognitive decline, progression of gray matter atrophy within temporal and parietal brain regions, and a trend for a faster decline in parietal Fludeoxyglucose (FDG)-PET metabolism. Changes in gray matter and FDG-PET mediated the association between Aβ and cognitive decline. In contrast, elderly cognitively healthy controls (HC) with high Aβ levels showed only a faster medial temporal lobe and precuneus volume decline compared with HC with low Aβ. In conclusion, the current results suggest not only that both functional and volumetric brain changes are associated with high Aβ years before the onset of dementia but also that HC with substantial Aβ levels show higher Aβ pathology resistance, lack other pathologies that condition neurotoxic effects of Aβ, or accumulated Aβ for a shorter time period.

AB - Beta-amyloid (Aβ) is a histopathological hallmark of Alzheimer's disease dementia, but high levels of Aβ in the brain can also be found in a substantial proportion of nondemented subjects. Here we investigated which 2-year rate of brain and cognitive changes are present in nondemented subjects with high and low Aβ levels, as assessed with cerebrospinal fluid and molecular positron emission tomography (PET)-based biomarkers of Aβ. In subjects with mild cognitive impairment, increased brain Aβ levels were associated with significantly faster cognitive decline, progression of gray matter atrophy within temporal and parietal brain regions, and a trend for a faster decline in parietal Fludeoxyglucose (FDG)-PET metabolism. Changes in gray matter and FDG-PET mediated the association between Aβ and cognitive decline. In contrast, elderly cognitively healthy controls (HC) with high Aβ levels showed only a faster medial temporal lobe and precuneus volume decline compared with HC with low Aβ. In conclusion, the current results suggest not only that both functional and volumetric brain changes are associated with high Aβ years before the onset of dementia but also that HC with substantial Aβ levels show higher Aβ pathology resistance, lack other pathologies that condition neurotoxic effects of Aβ, or accumulated Aβ for a shorter time period.

KW - Aβ

KW - FDG-PET

KW - MCI

KW - PIB-PET

UR - http://www.scopus.com/inward/record.url?scp=84864944776&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864944776&partnerID=8YFLogxK

U2 - 10.1093/cercor/bhr271

DO - 10.1093/cercor/bhr271

M3 - Article

C2 - 22038908

AN - SCOPUS:84864944776

VL - 22

SP - 1993

EP - 2004

JO - Cerebral Cortex

JF - Cerebral Cortex

SN - 1047-3211

IS - 9

ER -